Phaseline

Companies › Sichuan Kelun Pharmaceutical Research Institute

Sichuan Kelun Pharmaceutical Research Institute: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KLA480 injection–Phase 1Healthy ParticipantsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07030790KLA480 injectionPhase 1Healthy ParticipantsOtherDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.